|  | Choosing the Best Sample Collection Device for DTC Testing With at-home testing on the rise, there has been an increasing number of sample collection devices on the market. As a key component of the testing kit, it’s crucial to find the right device for your DTC company. Find out how to choose the best sample collection device with this free guide. Download Now. |
Featured Story | By Gabrielle Masson After two recent layoff rounds, BridgeBio Pharma is looking to out-license six of its candidates to save capital. The biotech has been hit by the burden of the bear market after disclosing disappointing phase 3 results last year. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Two bispecific antibodies have failed to make the grade at Xencor. The biotech is culling the pair of drug candidates in response to early-phase solid tumor studies that suggested they lack a competitive clinical profile. read more By Conor Hale The DNA sequencing giant will partner with the investment firm Deerfield Management to tackle the genetic underpinnings of disease, and it will also work with J&J's Janssen on cancer tests and research. read more Sponsored By: Lonza AG Exactly what you need from your DNA to IND partner to succeed. A unique guarantee of speed and quantity, backed by Lonza’s 35 years of experience in biologics, for a fixed price. read more By Nick Paul Taylor PepGen has refueled in the race to develop a next-generation rival to Sarepta’s Exondys. The biotech missed the bottom end of its IPO range but upped the share count, enabling it to reel in $108 million to challenge Sarepta for the Duchenne muscular dystrophy (DMD) market. read more Sponsored by: New York City Economic Development Corporation With a $1 billion public investment, diverse talent and science, space, and funding, NYC emerges as a global leader in life sciences. read more By Max Bayer VistaGen says regulators gave the green light to continue the development of its nasal spray to treat social anxiety without an additional abuse trial. The update comes as VistaGen expects data from its first phase 3 trial in the coming weeks. read more By James Waldron After announcing staff layoffs and an R&D pivot in March, the first evidence of Orion’s increased focus on pain management has materialized in the form of a licensing deal that will put it up against Vertex. Orion will pay Jemincare $15.9 million to develop and commercialize the preclinical, non-opioid pain therapy JMKX000623. read more By Kevin Dunleavy The FDA has restricted the use of the Johnson & Johnson COVID-19 vaccine because of the threat of rare but serious blood clots. The U.S. regulator is limiting use of the shot to those 18 and older who cannot access other vaccines or those who “elect to receive the Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19 vaccine.” read more By Zoey Becker The "Kingpin" defendants, who Gilead sued over a scheme to defraud the company's access program, settled for undisclosed amount and were permanently banned from the program. Court documents reveal how they were able to swindle millions from the drugmaker. read more By Fraiser Kansteiner Cystic fibrosis may be Vertex Pharmaceuticals’ commercial bread and butter, but the drugmaker shouldn’t be pigeonholed as a rare disease company, executives said on a call with analysts Thursday. The company's strategy is more about leveraging niche markets, they explained, flagging an “enormous” opportunity posed by the company’s closest commercial prospects in blood disorders and pain management. read more By Heather Landi Tempus, a company that uses artificial intelligence to advance precision medicine, has notched a partnership with the Department of Veterans Affairs to provide patients with cancer access to cutting-edge genetic testing to improve treatment. read more By Robert King An estimated 30 million people in the U.S. did not have insurance coverage last year, a slight improvement over the 31.6 million out of coverage in 2020. read more By Teresa Carey This week on "The Top Line," we discuss why Biogen’s overhaul reached the CEO level and dive into next steps at the company. We also discuss the most influential people in biopharma and the week's biggest headlines. read more By Max Bayer Biogen CEO Vounatsos is stepping down after a tumultuous year that included a bungled launch of the company's Alzheimer's treatment, Aduhelm. Pfizer vaccine R&D head Jansen slated to retire at the end of the year after overseeing the development of Comirnaty. Merck Research Laboratories continues to lose staff, this time bidding farewell to Green. read more By Angus Liu AstraZeneca and Daiichi Sankyo's Enhertu moves up the breast cancer treatment line. Biogen cut its Aduhelm sales team as its Eisai-led Alzheimer's asset moves into the spotlight. Two China-developed cancer drugs were hit with back-to-back FDA rejections. And more. read more Resources Sponsored by: Blue Matter, strategic consultants in the life sciences Recent trends are driving big changes in Medical Affairs. This paper explores why, and what MA teams can do to stay ahead of the curve. Sponsored by: PwC Don’t miss these critical considerations when evaluating your HCP interactions management program. Sponsored By: H1 More than 570 clinical trials in Ukraine have been disrupted. Unanticipated disruptions to medical testing and clinical trials impede progress toward new breakthroughs and new therapies that millions of patients around the world hang their hope on. What role do rescue sites play? Sponsored by: United Cargo The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now. Sponsored by: Thermo Fisher Scientific Learn how to position quality as a central component within your raw material sourcing strategies for the chemicals used throughout your workflows. Download the free whitepaper from Thermo Fisher Scientific. Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce Biotech Next Gen June 29-30, 2022 | Free Virtual Event Fierce Pharma PR & Communications Summit East July 19-20, 2022 | Jersey City, NJ Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 
